AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Allogene Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00KHRRDY2
1.25▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.25
Day's Range
1.16 – 1.26
52-Week Range
1.04 – 4.46
Volume
8.4M
Avg Volume
5.9M
Share Statistics
Shares Outstanding
Employees
152
Exchange
XNAS
Listed
2018-10-11
Share count as of August 10, 2026

Allogene Therapeutics, Inc. Common Stock (ALLO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Allogene Therapeutics, Inc. Common Stock (ALLO)
What is Allogene Therapeutics, Inc. Common Stock's Market Cap?
Allogene Therapeutics, Inc. Common Stock's Market Cap is $431.9M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Enterprise Value?
Allogene Therapeutics, Inc. Common Stock's Enterprise Value is $393.2M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Price / Sales?
Allogene Therapeutics, Inc. Common Stock's Price / Sales is 93.1×, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EV / Revenue?
Allogene Therapeutics, Inc. Common Stock's EV / Revenue is 84.7×, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EV / EBITDA?
Allogene Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Revenue (TTM)?
Allogene Therapeutics, Inc. Common Stock's Revenue (TTM) is $4.6M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Net Income (TTM)?
Allogene Therapeutics, Inc. Common Stock's Net Income (TTM) is -$165.5M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EBITDA?
Allogene Therapeutics, Inc. Common Stock's EBITDA is -$168.6M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Allogene Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.48, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EBITDA Margin?
Allogene Therapeutics, Inc. Common Stock's EBITDA Margin is -3634.7%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ALLOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue - related party—
YoY growth————
Operating expenses:
Research and development
General and administrative
Impairment of long-lived assets—
Total operating expenses
% of revenue1111.2%———
Loss from operations
% of revenue-1011.2%———
Other income (expenses), net:
Interest and other income, net
Interest expense
Other income (expenses), net
Total other income (expenses), net
Net loss
% of revenue-919.8%———
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)